



## Final Appraisal Recommendation

Advice No: 1019 – June 2019

**Eslicarbazepine acetate (Zebinix®) 200 mg and 800 mg tablets,  
and 50 mg/ml oral suspension**

**Limited submission by Eisai Ltd**

### Recommendation of the All Wales Medicines Strategy Group

**Eslicarbazepine acetate (Zebinix®) is recommended as an option for restricted use within NHS Wales.**

**Eslicarbazepine acetate (Zebinix®) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations, within its licensed indication as adjunctive therapy in adults, adolescents and children aged above six years, with partial-onset seizures, with or without secondary generalisation.**

**Eslicarbazepine acetate (Zebinix®) is not recommended for use within NHS Wales outside of this subpopulation.**

#### Additional note(s):

- This advice incorporates and replaces the existing AWMSG recommendation for eslicarbazepine acetate (Zebinix®) as an option for restricted use within NHS Wales. Eslicarbazepine acetate should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations, within its licensed indication as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation (advice number 3512, originally published November 2012).

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1214), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the

views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in June 2022. It will be reviewed again in three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1019: Eslicarbazepine acetate (Zebinix<sup>®</sup>) 200 mg and 800 mg tablets, and 50 mg/ml oral suspension. June 2019.